Kistler Tiffany Companies LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,594 shares of the company’s stock after selling 370 shares during the quarter. Johnson & Johnson comprises about 2.5% of Kistler Tiffany Companies LLC’s portfolio, making the stock its 9th biggest holding. Kistler Tiffany Companies LLC’s holdings in Johnson & Johnson were worth $5,370,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after acquiring an additional 841 shares during the period. Ullmann Financial Group Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $186,000. Taylor Wealth Management Partners boosted its stake in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after acquiring an additional 250 shares during the period. Finally, Puplava Financial Services Inc. bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $202,000. 66.06% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently commented on the company. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price for the company in a research note on Monday, October 30th. Citigroup Inc. lifted their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Jefferies Group LLC lifted their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, Barclays PLC lifted their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $143.70.
WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/05/johnson-johnson-jnj-holdings-decreased-by-kistler-tiffany-companies-llc.html.
Johnson & Johnson (JNJ) opened at $140.08 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.34 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a fifty-two week low of $109.32 and a fifty-two week high of $144.35. The firm has a market capitalization of $376,327.72, a price-to-earnings ratio of 19.62, a price-to-earnings-growth ratio of 2.85 and a beta of 0.82.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the firm earned $1.68 EPS. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. equities research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.